Literature DB >> 19520290

Cu(II) bis(thiosemicarbazone) radiopharmaceutical binding to serum albumin: further definition of species dependence and associated substituent effects.

Nathan E Basken1, Mark A Green.   

Abstract

INTRODUCTION: The pyruvaldehyde bis(N(4)-methylthiosemicarbazonato)copper(II) (Cu-PTSM) and diacetyl bis(N(4)-methylthiosemicarbazonato)copper(II) (Cu-ATSM) radiopharmaceuticals exhibit strong, species-dependent binding to the IIA site of human serum albumin (HSA), while the related ethylglyoxal bis(thiosemicarbazonato)copper(II) (Cu-ETS) radiopharmaceutical appears to exhibit only nonspecific binding to HSA and animal serum albumins.
METHODS: To further probe the structural basis for the species dependence of this albumin binding interaction, we examined protein binding of these three radiopharmaceuticals in solutions of albumin and/or serum from a broader array of mammalian species (rat, sheep, donkey, rabbit, cow, pig, dog, baboon, mouse, cat and elephant). We also evaluated the albumin binding of several copper(II) bis(thiosemicarbazone) chelates offering more diverse substitution of the ligand backbone.
RESULTS: Cu-PTSM and Cu-ATSM exhibit a strong interaction with HSA that is not apparent with the albumins of other species, while the binding of Cu-ETS to albumin is much less species dependent. The strong interaction of Cu-PTSM with HSA does not appear to simply correlate with variation, relative to the animal albumins, of a single amino acid lining HSA's IIA site. Those agents that selectively interact with HSA share the common feature of only methyl or hydrogen substitution at the carbon atoms of the diimine fragment of the ligand backbone.
CONCLUSIONS: The interspecies variations in albumin binding of Cu-PTSM and Cu-ATSM are not simply explained by unique amino acid substitutions in the IIA binding pocket of the serum albumins. However, the specific affinity for this region of HSA is disrupted when substituents bulkier than a methyl group appear on the imine carbons of the copper bis(thiosemicarbazone) chelate.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19520290      PMCID: PMC2736129          DOI: 10.1016/j.nucmedbio.2009.02.006

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  19 in total

1.  The characterization of two specific drug binding sites on human serum albumin.

Authors:  G Sudlow; D J Birkett; D N Wade
Journal:  Mol Pharmacol       Date:  1975-11       Impact factor: 4.436

Review 2.  Practical aspects of the ligand-binding and enzymatic properties of human serum albumin.

Authors:  Ulrich Kragh-Hansen; Victor Tuan Giam Chuang; Masaki Otagiri
Journal:  Biol Pharm Bull       Date:  2002-06       Impact factor: 2.233

3.  Further characterization of specific drug binding sites on human serum albumin.

Authors:  G Sudlow; D J Birkett; D N Wade
Journal:  Mol Pharmacol       Date:  1976-11       Impact factor: 4.436

4.  Mixed bis(thiosemicarbazone) ligands for the preparation of copper radiopharmaceuticals: synthesis and evaluation of tetradentate ligands containing two dissimilar thiosemicarbazone functions.

Authors:  J K Lim; C J Mathias; M A Green
Journal:  J Med Chem       Date:  1997-01-03       Impact factor: 7.446

5.  Crystal structure of human serum albumin complexed with fatty acid reveals an asymmetric distribution of binding sites.

Authors:  S Curry; H Mandelkow; P Brick; N Franks
Journal:  Nat Struct Biol       Date:  1998-09

6.  Structural basis of the drug-binding specificity of human serum albumin.

Authors:  Jamie Ghuman; Patricia A Zunszain; Isabelle Petitpas; Ananyo A Bhattacharya; Masaki Otagiri; Stephen Curry
Journal:  J Mol Biol       Date:  2005-10-14       Impact factor: 5.469

7.  Species differences of serum albumins: I. Drug binding sites.

Authors:  T Kosa; T Maruyama; M Otagiri
Journal:  Pharm Res       Date:  1997-11       Impact factor: 4.200

8.  Synthesis and evaluation of copper radiopharmaceuticals with mixed bis(thiosemicarbazone) ligands.

Authors:  L J Ackerman; D X West; C J Mathias; M A Green
Journal:  Nucl Med Biol       Date:  1999-07       Impact factor: 2.408

9.  Crystal structure analysis of warfarin binding to human serum albumin: anatomy of drug site I.

Authors:  I Petitpas; A A Bhattacharya; S Twine; M East; S Curry
Journal:  J Biol Chem       Date:  2001-04-02       Impact factor: 5.157

10.  Species-dependent binding of copper(II) bis(thiosemicarbazone) radiopharmaceuticals to serum albumin.

Authors:  C J Mathias; S R Bergmann; M A Green
Journal:  J Nucl Med       Date:  1995-08       Impact factor: 10.057

View more
  7 in total

1.  Prokineticin receptor 1 antagonist PC-10 as a biomarker for imaging inflammatory pain.

Authors:  Orit Jacobson; Ido D Weiss; Gang Niu; Gianfranco Balboni; Cenzo Congiu; Valentina Onnis; Dale O Kiesewetter; Roberta Lattanzi; Severo Salvadori; Xiaoyuan Chen
Journal:  J Nucl Med       Date:  2011-03-18       Impact factor: 10.057

Review 2.  A brief overview of metal complexes as nuclear imaging agents.

Authors:  Douglas S MacPherson; Kimberly Fung; Brendon E Cook; Lynn C Francesconi; Brian M Zeglis
Journal:  Dalton Trans       Date:  2019-10-07       Impact factor: 4.390

3.  Molecular imaging biomarkers of resistance to radiation therapy for spontaneous nasal tumors in canines.

Authors:  Tyler J Bradshaw; Stephen R Bowen; Michael A Deveau; Lyndsay Kubicek; Pamela White; Søren M Bentzen; Richard J Chappell; Lisa J Forrest; Robert Jeraj
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-03-15       Impact factor: 7.038

4.  Heterogeneity in intratumor correlations of 18F-FDG, 18F-FLT, and 61Cu-ATSM PET in canine sinonasal tumors.

Authors:  Tyler J Bradshaw; Stephen R Bowen; Ngoneh Jallow; Lisa J Forrest; Robert Jeraj
Journal:  J Nucl Med       Date:  2013-09-16       Impact factor: 10.057

Review 5.  The clinical importance of assessing tumor hypoxia: relationship of tumor hypoxia to prognosis and therapeutic opportunities.

Authors:  Joseph C Walsh; Artem Lebedev; Edward Aten; Kathleen Madsen; Liane Marciano; Hartmuth C Kolb
Journal:  Antioxid Redox Signal       Date:  2014-05-09       Impact factor: 8.401

6.  Performance of a ⁶²Zn/⁶²Cu microgenerator in kit-based synthesis and delivery of [⁶²Cu]Cu-ETS for PET perfusion imaging.

Authors:  Yen Ng; Jeffrey L Lacy; James W Fletcher; Mark A Green
Journal:  Appl Radiat Isot       Date:  2014-05-22       Impact factor: 1.513

Review 7.  Focus on the Controversial Aspects of (64)Cu-ATSM in Tumoral Hypoxia Mapping by PET Imaging.

Authors:  Mathilde Colombié; Sébastien Gouard; Mathieu Frindel; Aurélien Vidal; Michel Chérel; Françoise Kraeber-Bodéré; Caroline Rousseau; Mickaël Bourgeois
Journal:  Front Med (Lausanne)       Date:  2015-08-24
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.